Showing results (41-50 of 488) with videos related to
Sort By:
Pageof 49
Journal of Inflammation Research|November 19, 2011
The role of the NLRP3 inflammasome in goutSarah R Kingsbury, Philip G Conaghan, Michael F McDermottExpert Opinion on Drug Safety|May 15, 2013
Safety evaluation of leflunomide in rheumatoid arthritisHelen I Keen, Philip G Conaghan, Susan E TettAnnals of the Rheumatic Diseases|September 1, 2010
Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritisGlenn Haugeberg, Sarah Morton, Paul Emery, et al.Expert Opinion on Therapeutic Targets|October 25, 2024
Targeting the TRPV1 pain pathway in osteoarthritis of the kneeAli Mobasheri, François Rannou, Stefan Ivanavicius, et al.The Journal of Rheumatology|April 17, 2004
A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the kneeRichard Day, Peter Brooks, Philip G Conaghan, et al.BMC Musculoskeletal Disorders|February 2, 2022
Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritisPhilip G Conaghan, Lucy Abraham, Lars Viktrup, et al.Evidence-Based Medicine|September 4, 2017
Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic reviewMuhammad Abdul Hadi, Gretl A McHugh, Philip G ConaghanBest Practice & Research. Clinical Rheumatology|December 25, 2015
Monitoring in established RA: Role of imaging and soluble biomarkersJoshua F Baker, York Kiat Tan, Philip G ConaghanCurrent Pharmaceutical Design|March 12, 2015
Biological therapies in osteoarthritisClaire Y J Wenham, Michael McDermott, Philip G ConaghanOsteoarthritis and Cartilage|March 4, 2026
Digital mobility measures in osteoarthritis: endpoint innovation without losing what mattersRobin Christensen, Philip Rask Lage-Hansen, Philip G ConaghanPageof 49